-
1
-
-
70949107842
-
Inflammatory bowel disease
-
Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
-
(2009)
N Engl J Med
, vol.361
, pp. 2066-2078
-
-
Abraham, C.1
Cho, J.H.2
-
2
-
-
79955561083
-
Epidemiology and natural history of inflammatory bowel diseases
-
Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140: 1785-1794.
-
(2011)
Gastroenterology
, vol.140
, pp. 1785-1794
-
-
Cosnes, J.1
Gower-Rousseau, C.2
Seksik, P.3
-
3
-
-
84868336049
-
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
-
Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
-
(2012)
Nature
, vol.491
, pp. 119-124
-
-
Jostins, L.1
Ripke, S.2
Weersma, R.K.3
-
4
-
-
79959216005
-
Genetics and pathogenesis of inflammatory bowel disease
-
Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
-
(2011)
Nature
, vol.474
, pp. 307-317
-
-
Khor, B.1
Gardet, A.2
Xavier, R.J.3
-
5
-
-
79751472562
-
The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organization: When to start, when to stop, which drug to choose, and how to predict response?
-
D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 199-212
-
-
D'Haens, G.R.1
Panaccione, R.2
Higgins, P.D.3
-
6
-
-
39449085441
-
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial
-
D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
-
(2008)
Lancet
, vol.371
, pp. 660-667
-
-
D'Haens, G.1
Baert, F.2
Van Assche, G.3
-
7
-
-
0036061640
-
Long-term evolution of disease behavior of Crohn's disease
-
Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
-
(2002)
Inflamm Bowel Dis
, vol.8
, pp. 244-250
-
-
Cosnes, J.1
Cattan, S.2
Blain, A.3
-
9
-
-
0029875942
-
Changes in extent of ulcerative colitis: A study on the course and prognostic factors
-
Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260-266.
-
(1996)
Scand J Gastroenterol
, vol.31
, pp. 260-266
-
-
Langholz, E.1
Munkholm, P.2
Davidsen, M.3
-
10
-
-
62049083383
-
Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review
-
Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104:760-767.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 760-767
-
-
Gisbert, J.P.1
Panes, J.2
-
11
-
-
77950988234
-
Infliximab, azathioprine, or combination therapy for Crohn's disease
-
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
-
(2010)
N Engl J Med
, vol.362
, pp. 1383-1395
-
-
Colombel, J.F.1
Sandborn, W.J.2
Reinisch, W.3
-
12
-
-
0036202336
-
The molecular classification of the clinical manifestations of Crohn's disease
-
Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122: 854-866.
-
(2002)
Gastroenterology
, vol.122
, pp. 854-866
-
-
Ahmad, T.1
Armuzzi, A.2
Bunce, M.3
-
13
-
-
0036725827
-
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
-
Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-688.
-
(2002)
Gastroenterology
, vol.123
, pp. 679-688
-
-
Abreu, M.T.1
Taylor, K.D.2
Lin, Y.C.3
-
14
-
-
34247566585
-
A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5
-
Prescott NJ, Fisher SA, Franke A, et al. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology. 2007;132:1665-1671.
-
(2007)
Gastroenterology
, vol.132
, pp. 1665-1671
-
-
Prescott, N.J.1
Fisher, S.A.2
Franke, A.3
-
15
-
-
56249135538
-
A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells
-
Virgin HWt
-
Cadwell K, Liu JY, Brown SL, et al, Virgin HWt. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature. 2008;456:259-263.
-
(2008)
Nature
, vol.456
, pp. 259-263
-
-
Cadwell, K.1
Liu, J.Y.2
Brown, S.L.3
-
16
-
-
77957682295
-
ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis
-
1641.e1-2
-
Homer CR, Richmond AL, Rebert NA, et al. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology. 2010;139:1630-1641, 1641.e1-2.
-
(2010)
Gastroenterology
, vol.139
, pp. 1630-1641
-
-
Homer, C.R.1
Richmond, A.L.2
Rebert, N.A.3
-
17
-
-
84887212530
-
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease
-
Koslowski MJ, Kubler I, Chamaillard M, et al. Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One. 2009;4:e4496.
-
(2009)
PLoS One
, vol.4
-
-
Koslowski, M.J.1
Kubler, I.2
Chamaillard, M.3
-
18
-
-
33748675295
-
The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease
-
Thalmaier D, Dambacher J, Seiderer J, et al. The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease. Aliment Pharmacol Ther. 2006;24:1105-1115.
-
(2006)
Aliment Pharmacol Ther
, vol.24
, pp. 1105-1115
-
-
Thalmaier, D.1
Dambacher, J.2
Seiderer, J.3
-
19
-
-
77956407594
-
Evidence for STAT4 as a common autoimmune gene: Rs7574865 is associated with colonic Crohn's disease and early disease onset
-
Glas J, Seiderer J, Nagy M, et al. Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. PLoS One. 2010;5:e10373.
-
(2010)
PLoS One
, vol.5
-
-
Glas, J.1
Seiderer, J.2
Nagy, M.3
-
20
-
-
13744263989
-
HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: A critical reappraisal with review of the literature
-
discussion 64-5
-
Annese V, Piepoli A, Latiano A, et al. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis Colon Rectum. 2005;48:57-64; discussion 64-5.
-
(2005)
Dis Colon Rectum
, vol.48
, pp. 57-64
-
-
Annese, V.1
Piepoli, A.2
Latiano, A.3
-
21
-
-
19144364861
-
Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: Association with clinical phenotypes
-
Waschke KA, Villani AC, Vermeire S, et al. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. Am J Gastroenterol. 2005;100:1126-1133.
-
(2005)
Am J Gastroenterol
, vol.100
, pp. 1126-1133
-
-
Waschke, K.A.1
Villani, A.C.2
Vermeire, S.3
-
22
-
-
33846171221
-
Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease
-
Dambacher J, Staudinger T, Seiderer J, et al. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm Bowel Dis. 2007;13:71-82.
-
(2007)
Inflamm Bowel Dis
, vol.13
, pp. 71-82
-
-
Dambacher, J.1
Staudinger, T.2
Seiderer, J.3
-
23
-
-
69249152654
-
Genetic risk profiling and prediction of disease course in Crohn's disease patients
-
Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol. 2009;7:972-980.e2.
-
(2009)
Clin Gastroenterol Hepatol
, vol.7
, pp. 972-980
-
-
Henckaerts, L.1
Van Steen, K.2
Verstreken, I.3
-
24
-
-
79953771887
-
The prognostic power of the NOD2 genotype for complicated Crohn's disease: A meta-analysis
-
Adler J, Rangwalla SC, Dwamena BA, et al. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol. 2011;106:699-712.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 699-712
-
-
Adler, J.1
Rangwalla, S.C.2
Dwamena, B.A.3
-
25
-
-
13744264167
-
Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease-an IG-IBD study
-
Annese V, Lombardi G, Perri F, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease-an IG-IBD study. Am J Gastroenterol. 2005;100:84-92.
-
(2005)
Am J Gastroenterol
, vol.100
, pp. 84-92
-
-
Annese, V.1
Lombardi, G.2
Perri, F.3
-
26
-
-
60749133895
-
Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease
-
Latiano A, Palmieri O, Cucchiara S, et al. Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease. Am J Gastroenterol. 2009;104:110-116.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 110-116
-
-
Latiano, A.1
Palmieri, O.2
Cucchiara, S.3
-
27
-
-
61649123125
-
Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort
-
Weersma RK, Stokkers PC, van Bodegraven AA, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut. 2009;58:388-395.
-
(2009)
GUT
, vol.58
, pp. 388-395
-
-
Weersma, R.K.1
Stokkers, P.C.2
Van Bodegraven, A.A.3
-
28
-
-
84860389274
-
NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease
-
Strober W, Watanabe T. NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease. Mucosal Immunol. 2011;4:484-495.
-
(2011)
Mucosal Immunol
, vol.4
, pp. 484-495
-
-
Strober, W.1
Watanabe, T.2
-
29
-
-
27644562698
-
Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence
-
Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005;242:693-700.
-
(2005)
Ann Surg
, vol.242
, pp. 693-700
-
-
Alvarez-Lobos, M.1
Arostegui, J.I.2
Sans, M.3
-
30
-
-
9144271221
-
CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease
-
Kugathasan S, Collins N, Maresso K, et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:1003-1009.
-
(2004)
Clin Gastroenterol Hepatol
, vol.2
, pp. 1003-1009
-
-
Kugathasan, S.1
Collins, N.2
Maresso, K.3
-
31
-
-
77955904069
-
NOD2 mutations predict the risk for surgery in pediatric-onset Crohn's disease
-
Lacher M, Helmbrecht J, Schroepf S, et al. NOD2 mutations predict the risk for surgery in pediatric-onset Crohn's disease. J Pediatr Surg. 2010; 45:1591-1597.
-
(2010)
J Pediatr Surg
, vol.45
, pp. 1591-1597
-
-
Lacher, M.1
Helmbrecht, J.2
Schroepf, S.3
-
32
-
-
84857943512
-
Mutations in IRGM are associated with more frequent need for surgery in patients with ileocolonic Crohn's disease
-
Sehgal R, Berg A, Polinski JI, et al. Mutations in IRGM are associated with more frequent need for surgery in patients with ileocolonic Crohn's disease. Dis Colon Rectum. 2012;55:115-121.
-
(2012)
Dis Colon Rectum
, vol.55
, pp. 115-121
-
-
Sehgal, R.1
Berg, A.2
Polinski, J.I.3
-
33
-
-
70350507268
-
CARD15 gene variants and risk of reoperation in Crohn's disease patients
-
Maconi G, Colombo E, Sampietro GM, et al. CARD15 gene variants and risk of reoperation in Crohn's disease patients. Am J Gastroenterol. 2009; 104:2483-2491.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 2483-2491
-
-
MacOni, G.1
Colombo, E.2
Sampietro, G.M.3
-
34
-
-
79959652551
-
Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: A systematic review
-
W-295-8
-
Booth RA, Ansari MT, Loit E, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med. 2011;154:814-823, W-295-8.
-
(2011)
Ann Intern Med
, vol.154
, pp. 814-823
-
-
Booth, R.A.1
Ansari, M.T.2
Loit, E.3
-
35
-
-
27744574836
-
A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
-
Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005; 100:2239-2247.
-
(2005)
Am J Gastroenterol
, vol.100
, pp. 2239-2247
-
-
Dubinsky, M.C.1
Reyes, E.2
Ofman, J.3
-
36
-
-
80053525084
-
A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine
-
Zabala-Fernandez W, Barreiro-de Acosta M, Echarri A, et al. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine. J Gastrointestin Liver Dis. 2011;20:247-253.
-
(2011)
J Gastrointestin Liver Dis
, vol.20
, pp. 247-253
-
-
Zabala-Fernandez, W.1
Barreiro-De Acosta, M.2
Echarri, A.3
-
37
-
-
0035050836
-
ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease
-
Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001;120:1347-1355.
-
(2001)
Gastroenterology
, vol.120
, pp. 1347-1355
-
-
Taylor, K.D.1
Plevy, S.E.2
Yang, H.3
-
38
-
-
33645904838
-
Lymphotoxin alpha gene in Crohn's disease patients: Absence of implication in the response to infliximab in a large cohort study
-
Dideberg V, Louis E, Farnir F, et al. Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet Genomics. 2006;16:369-373.
-
(2006)
Pharmacogenet Genomics
, vol.16
, pp. 369-373
-
-
Dideberg, V.1
Louis, E.2
Farnir, F.3
-
39
-
-
0035988896
-
A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism
-
Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37:818-824.
-
(2002)
Scand J Gastroenterol
, vol.37
, pp. 818-824
-
-
Louis, E.1
Vermeire, S.2
Rutgeerts, P.3
-
40
-
-
0036367145
-
Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab
-
Mascheretti S, Hampe J, Kuhbacher T, et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J. 2002;2: 127-136.
-
(2002)
Pharmacogenomics J
, vol.2
, pp. 127-136
-
-
Mascheretti, S.1
Hampe, J.2
Kuhbacher, T.3
-
41
-
-
12144287977
-
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
-
Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2004;19:511-519.
-
(2004)
Aliment Pharmacol Ther
, vol.19
, pp. 511-519
-
-
Louis, E.1
El Ghoul, Z.2
Vermeire, S.3
-
42
-
-
33751108526
-
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: A subanalysis of the ACCENT i study
-
Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics. 2006;16:911-914.
-
(2006)
Pharmacogenet Genomics
, vol.16
, pp. 911-914
-
-
Louis, E.J.1
Watier, H.E.2
Schreiber, S.3
-
43
-
-
18644366895
-
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: An analysis in 534 patients from two multicenter, prospective GCP-level trials
-
Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics. 2002;12:509-515.
-
(2002)
Pharmacogenetics
, vol.12
, pp. 509-515
-
-
Mascheretti, S.1
Hampe, J.2
Croucher, P.J.3
-
44
-
-
0036305537
-
NOD2/CARD15 does not influence response to infliximab in Crohn's disease
-
Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology. 2002; 123:106-111.
-
(2002)
Gastroenterology
, vol.123
, pp. 106-111
-
-
Vermeire, S.1
Louis, E.2
Rutgeerts, P.3
-
45
-
-
14844362492
-
IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab
-
Urcelay E, Mendoza JL, Martinez A, et al. IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. World J Gastroenterol. 2005;11:1187-1192.
-
(2005)
World J Gastroenterol
, vol.11
, pp. 1187-1192
-
-
Urcelay, E.1
Mendoza, J.L.2
Martinez, A.3
-
46
-
-
26244456815
-
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
-
Hlavaty T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther. 2005;22:613-626.
-
(2005)
Aliment Pharmacol Ther
, vol.22
, pp. 613-626
-
-
Hlavaty, T.1
Pierik, M.2
Henckaerts, L.3
-
47
-
-
34247638361
-
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors
-
Hlavaty T, Ferrante M, Henckaerts L, et al. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis. 2007;13:372-379.
-
(2007)
Inflamm Bowel Dis
, vol.13
, pp. 372-379
-
-
Hlavaty, T.1
Ferrante, M.2
Henckaerts, L.3
-
48
-
-
14944341671
-
Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis
-
Ho GT, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005;128:288-296.
-
(2005)
Gastroenterology
, vol.128
, pp. 288-296
-
-
Ho, G.T.1
Nimmo, E.R.2
Tenesa, A.3
-
49
-
-
78249287838
-
Genetic predictors of medically refractory ulcerative colitis
-
Haritunians T, Taylor KD, Targan SR, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16:1830-1840.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 1830-1840
-
-
Haritunians, T.1
Taylor, K.D.2
Targan, S.R.3
-
50
-
-
79955928909
-
Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease
-
De Iudicibus S, Franca R, Martelossi S, et al. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol. 2011;17:1095-1108.
-
(2011)
World J Gastroenterol
, vol.17
, pp. 1095-1108
-
-
De Iudicibus, S.1
Franca, R.2
Martelossi, S.3
-
51
-
-
0034903792
-
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
-
Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
-
(2001)
Gastroenterology
, vol.121
, pp. 255-260
-
-
Faubion Jr., W.A.1
Loftus Jr., E.V.2
Harmsen, W.S.3
-
52
-
-
33846157742
-
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis
-
Daniel F, Loriot MA, Seksik P, et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007;13:19-23.
-
(2007)
Inflamm Bowel Dis
, vol.13
, pp. 19-23
-
-
Daniel, F.1
Loriot, M.A.2
Seksik, P.3
-
53
-
-
8844229534
-
Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis
-
Potocnik U, Ferkolj I, Glavac D, et al. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 2004;5:530-539.
-
(2004)
Genes Immun
, vol.5
, pp. 530-539
-
-
Potocnik, U.1
Ferkolj, I.2
Glavac, D.3
-
54
-
-
77949524420
-
High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis
-
Yamamoto-Furusho JK, Villeda-Ramirez MA, Fonseca-Camarillo G, et al. High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. Inflamm Bowel Dis. 2010;16:541-542.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 541-542
-
-
Yamamoto-Furusho, J.K.1
Villeda-Ramirez, M.A.2
Fonseca-Camarillo, G.3
-
55
-
-
77953787089
-
Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease
-
Dubinsky MC, Mei L, Friedman M, et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1357-1366.
-
(2010)
Inflamm Bowel Dis
, vol.16
, pp. 1357-1366
-
-
Dubinsky, M.C.1
Mei, L.2
Friedman, M.3
-
56
-
-
84876411425
-
Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II)
-
Duraes C, Machado JC, Portela F, et al. Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II). Inflamm Bowel Dis. 2013;19:230-239.
-
(2013)
Inflamm Bowel Dis
, vol.19
, pp. 230-239
-
-
Duraes, C.1
MacHado, J.C.2
Portela, F.3
-
57
-
-
72549108185
-
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
-
Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612-1619.
-
(2009)
GUT
, vol.58
, pp. 1612-1619
-
-
Arijs, I.1
Li, K.2
Toedter, G.3
-
58
-
-
77955426386
-
Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis
-
Jurgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811-1819.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 1811-1819
-
-
Jurgens, M.1
Laubender, R.P.2
Hartl, F.3
-
59
-
-
33747454249
-
Distinct phenotype of early childhood inflammatory bowel disease
-
Paul T, Birnbaum A, Pal DK, et al. Distinct phenotype of early childhood inflammatory bowel disease. J Clin Gastroenterol. 2006;40:583-586.
-
(2006)
J Clin Gastroenterol
, vol.40
, pp. 583-586
-
-
Paul, T.1
Birnbaum, A.2
Pal, D.K.3
-
60
-
-
0029810041
-
Crohn's disease: Influence of age at diagnosis on site and clinical type of disease
-
Polito JM II, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996; 111:580-586.
-
(1996)
Gastroenterology
, vol.111
, pp. 580-586
-
-
Polito, I.I.J.M.1
Childs, B.2
Mellits, E.D.3
-
61
-
-
34548651642
-
Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adultonset Crohn's disease
-
de Ridder L, Weersma RK, Dijkstra G, et al. Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adultonset Crohn's disease. Inflamm Bowel Dis. 2007;13:1083-1092.
-
(2007)
Inflamm Bowel Dis
, vol.13
, pp. 1083-1092
-
-
De Ridder, L.1
Weersma, R.K.2
Dijkstra, G.3
-
62
-
-
33646061100
-
Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease
-
Russell RK, Drummond HE, Nimmo ER, et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut. 2006;55: 1114-1123.
-
(2006)
GUT
, vol.55
, pp. 1114-1123
-
-
Russell, R.K.1
Drummond, H.E.2
Nimmo, E.R.3
-
63
-
-
70649113728
-
Common variants at five new loci associated with early-onset inflammatory bowel disease
-
Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009;41:1335-1340.
-
(2009)
Nat Genet
, vol.41
, pp. 1335-1340
-
-
Imielinski, M.1
Baldassano, R.N.2
Griffiths, A.3
-
64
-
-
0036731117
-
Uveitis and erythema nodosum in inflammatory bowel disease: Clinical features and the role of HLA genes
-
Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology. 2002;123:714-718.
-
(2002)
Gastroenterology
, vol.123
, pp. 714-718
-
-
Orchard, T.R.1
Chua, C.N.2
Ahmad, T.3
-
65
-
-
0033973568
-
Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease
-
Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000;118:274-278.
-
(2000)
Gastroenterology
, vol.118
, pp. 274-278
-
-
Orchard, T.R.1
Thiyagaraja, S.2
Welsh, K.I.3
-
66
-
-
70449725001
-
FcRL3 gene promoter variant is associated with peripheral arthritis in Crohn's disease
-
Mendoza JL, Lana R, Martin MC, et al. FcRL3 gene promoter variant is associated with peripheral arthritis in Crohn's disease. Inflamm Bowel Dis. 2009;15:1351-1357.
-
(2009)
Inflamm Bowel Dis
, vol.15
, pp. 1351-1357
-
-
Mendoza, J.L.1
Lana, R.2
Martin, M.C.3
-
67
-
-
77249164222
-
Genome-wide association analysis in primary sclerosing cholangitis
-
Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102-1111.
-
(2010)
Gastroenterology
, vol.138
, pp. 1102-1111
-
-
Karlsen, T.H.1
Franke, A.2
Melum, E.3
-
68
-
-
79957502386
-
Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9
-
Janse M, Lamberts LE, Franke L, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology. 2011;53:1977-1985.
-
(2011)
Hepatology
, vol.53
, pp. 1977-1985
-
-
Janse, M.1
Lamberts, L.E.2
Franke, L.3
-
69
-
-
78651227093
-
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci
-
Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43:17-19.
-
(2011)
Nat Genet
, vol.43
, pp. 17-19
-
-
Melum, E.1
Franke, A.2
Schramm, C.3
-
70
-
-
78249231419
-
Effect of interactions of glutathione S-transferase T1, M1, and P1 and HMOX1 gene promoter polymorphisms with heavy smoking on the risk of rheumatoid arthritis
-
Keenan BT, Chibnik LB, Cui J, et al. Effect of interactions of glutathione S-transferase T1, M1, and P1 and HMOX1 gene promoter polymorphisms with heavy smoking on the risk of rheumatoid arthritis. Arthritis Rheum. 2010;62:3196-3210.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 3196-3210
-
-
Keenan, B.T.1
Chibnik, L.B.2
Cui, J.3
-
71
-
-
80052681515
-
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk
-
Wassenaar CA, Dong Q, Wei Q, et al. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst. 2011;103:1342-1346.
-
(2011)
J Natl Cancer Inst
, vol.103
, pp. 1342-1346
-
-
Wassenaar, C.A.1
Dong, Q.2
Wei, Q.3
-
73
-
-
84860184315
-
Characterization of geneenvironment interactions for colorectal cancer susceptibility loci
-
Hutter CM, Chang-Claude J, Slattery ML, et al. Characterization of geneenvironment interactions for colorectal cancer susceptibility loci. Cancer Res. 2012;72:2036-2044.
-
(2012)
Cancer Res
, vol.72
, pp. 2036-2044
-
-
Hutter, C.M.1
Chang-Claude, J.2
Slattery, M.L.3
-
74
-
-
84858285593
-
Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human
-
Ichimura A, Hirasawa A, Poulain-Godefroy O, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature. 2012; 483:350-354.
-
(2012)
Nature
, vol.483
, pp. 350-354
-
-
Ichimura, A.1
Hirasawa, A.2
Poulain-Godefroy, O.3
-
75
-
-
80455162391
-
Exposure science and the exposome: An opportunity for coherence in the environmental health sciences
-
Lioy PJ, Rappaport SM. Exposure science and the exposome: an opportunity for coherence in the environmental health sciences. Environ Health Perspect. 2011;119:A466-A467.
-
(2011)
Environ Health Perspect
, vol.119
-
-
Lioy, P.J.1
Rappaport, S.M.2
-
76
-
-
79958119436
-
Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease
-
Lin Z, Hegarty JP, Cappel JA, et al. Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. Clin Genet. 2011;80:59-67.
-
(2011)
Clin Genet
, vol.80
, pp. 59-67
-
-
Lin, Z.1
Hegarty, J.P.2
Cappel, J.A.3
-
77
-
-
84858700966
-
Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers
-
Olaru AV, Cheng Y, Agarwal R, et al. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers. Inflamm Bowel Dis. 2012;18:641-648.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. 641-648
-
-
Olaru, A.V.1
Cheng, Y.2
Agarwal, R.3
-
78
-
-
73649123907
-
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
-
Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
-
(2010)
Cancer Cell
, vol.17
, pp. 98-110
-
-
Verhaak, R.G.1
Hoadley, K.A.2
Purdom, E.3
-
79
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
80
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537.
-
(2005)
Lancet
, vol.366
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
-
81
-
-
77953881002
-
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
-
Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-129.e18.
-
(2010)
Gastroenterology
, vol.139
, pp. 120-129
-
-
Thompson, A.J.1
Muir, A.J.2
Sulkowski, M.S.3
|